NCT05868161 Pounce™ Thrombectomy System Retrospective Registry
| NCT ID | NCT05868161 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SurModics, Inc. |
| Condition | Peripheral Arterial Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-04-18 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-04-18 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PROWL registry is an open-label retrospective, multi-center, US study of the Surmodics™ Pounce™ Thrombectomy System for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
Eligibility Criteria
Inclusion Criteria: * Subject underwent an endovascular intervention where the Pounce Thrombectomy System was attempted * Subject is willing and able to provide informed consent prior to the collection of study data or a consent waiver is in place Exclusion Criteria: * Subject is under the age of 18 years
Contact & Investigator
Sean Lyden, MD
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT05868161 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peripheral Arterial Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05868161 currently recruiting?
Yes, NCT05868161 is actively recruiting participants. Contact the research team at PROWLRegistry@surmodics.com for enrollment information.
Where is the NCT05868161 trial being conducted?
This trial is being conducted at Peoria, United States, Munster, United States, Baton Rouge, United States, Minneapolis, United States and 5 additional locations.
Who is sponsoring the NCT05868161 clinical trial?
NCT05868161 is sponsored by SurModics, Inc.. The principal investigator is Sean Lyden, MD at The Cleveland Clinic. The trial plans to enroll 500 participants.